Heliprobe® System is a Urea Breath Test perfectly suited for primary diagnosis and for post treatment follow-up of Helicobacter pylori infection. It is a reliable, safe and cost-effective testing system.
Heliprobe® System is a method with unique advantages:
Convenience – Easy to use, near patient testing,no need to send sample for analysis
Comfort – Painless, no invasive gastroscopic tubing
Speed – Samples are ready for analysis in only 10 minutes with test result available in 5 minutes
Reliability – Sensitivity 95 % and specificity 100 %
Helicobacter pylori (H. pylori), previously named Campylobacter is a Gram-negative, microaerophilic bacterium found in the stomach. It was identified in 1982 by Barry Marshall and Robin Warren, who found that it was present in patients with chronic gastritis and gastric ulcers. It is also linked to the development of duodenal ulcers and stomach cancer. However, over 80 percent of individuals infected with the bacterium are asymptomatic and it has been postulated that it may play an important role in the natural stomach ecology.More than 50% of the world''s population harbor H. pylori in their upper gastrointestinal tract.
Once H. pylori is detected in a person with a peptic ulcer, the normal procedure is to eradicate it and allow the ulcer to heal. The standard first-line therapy is a one week "triple therapy" consisting of proton pump inhibitors such as omeprazole and the antibiotics clarithromycin and amoxicillin. Variations of the triple therapy have been developed over the years, such as using a different proton pump inhibitor, as with pantoprazole or rabeprazole, or replacing amoxicillin with metronidazole for people who are allergic to penicillin.
Such a therapy has revolutionized the treatment of peptic ulcers, and has made a cure to the disease possible; previously, the only option was symptom control using antacids, H2-antagonists or proton pump inhibitors alone.